File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Primary Chemotherapy and Radiation as a Treatment Strategy for HPV-Positive Oropharyngeal Cancer

TitlePrimary Chemotherapy and Radiation as a Treatment Strategy for HPV-Positive Oropharyngeal Cancer
Authors
Issue Date2012
Citation
Head and Neck Pathology, 2012, v. 6 n. SUPPL. 1, p. 91-97 How to Cite?
AbstractThe incidence of human papillomavirus-positive oropharyngeal cancer (HPV/OPSCC) is rapidly increasing, which will represent a major public health burden for decades to come. Although HPV/OPSCC is generally associated with a better prognosis than HPV-negative OPSCC, the survival rate of individuals with higher-risk clinical and pathologic features remains unchanged. Emerging evidence suggests that HPV/OPSCC is pathologically and molecularly distinct from HPV-negative OPSCC. This review focuses on summarizing treatment strategies for HPV/OPSCC by reviewing the peer-reviewed literature and noting ongoing and planned clinical trials in this disease. We also discuss the potential of designing targeted therapy based on the recent genomic findings of HPV/OPSCC. © 2012 Springer Science+Business Media, LLC.
Persistent Identifierhttp://hdl.handle.net/10722/194431
ISSN
2015 SCImago Journal Rankings: 1.016

 

DC FieldValueLanguage
dc.contributor.authorLui, VWY-
dc.contributor.authorGrandis, JR-
dc.date.accessioned2014-01-30T03:32:35Z-
dc.date.available2014-01-30T03:32:35Z-
dc.date.issued2012-
dc.identifier.citationHead and Neck Pathology, 2012, v. 6 n. SUPPL. 1, p. 91-97-
dc.identifier.issn1936-055X-
dc.identifier.urihttp://hdl.handle.net/10722/194431-
dc.description.abstractThe incidence of human papillomavirus-positive oropharyngeal cancer (HPV/OPSCC) is rapidly increasing, which will represent a major public health burden for decades to come. Although HPV/OPSCC is generally associated with a better prognosis than HPV-negative OPSCC, the survival rate of individuals with higher-risk clinical and pathologic features remains unchanged. Emerging evidence suggests that HPV/OPSCC is pathologically and molecularly distinct from HPV-negative OPSCC. This review focuses on summarizing treatment strategies for HPV/OPSCC by reviewing the peer-reviewed literature and noting ongoing and planned clinical trials in this disease. We also discuss the potential of designing targeted therapy based on the recent genomic findings of HPV/OPSCC. © 2012 Springer Science+Business Media, LLC.-
dc.languageeng-
dc.relation.ispartofHead and Neck Pathology-
dc.titlePrimary Chemotherapy and Radiation as a Treatment Strategy for HPV-Positive Oropharyngeal Cancer-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1007/s12105-012-0364-5-
dc.identifier.pmid22782228-
dc.identifier.scopuseid_2-s2.0-84864138332-
dc.identifier.volume6-
dc.identifier.issueSUPPL. 1-
dc.identifier.spage91-
dc.identifier.epage97-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats